
| Disease Domain | Count | 
|---|---|
| Hemic and Lymphatic Diseases | 1 | 
| Neoplasms | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 1 | 
| Top 5 Target | Count | 
|---|---|
| Class IIA HDACs(Histone deacetylases, class IIA) | 1 | 
| Target | 
| Mechanism Class IIA HDACs inhibitors [+1]  | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date01 Sep 2025 | 
| Sponsor / Collaborator  University of Bern  [+5]  | 
| Start Date01 Oct 2024 | 
| Sponsor / Collaborator  [+2]  | 
| Start Date30 Sep 2024 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| TMP269(  Class IIA HDACs ) | Acute Myeloid Leukemia More | Preclinical | 





